Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00091572
Status:
COMPLETED
Last Update Posted:
2017-06-06
First Post:
2004-09-10
Brief Title:
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma Study P03267
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
Extended Schedule Escalated Dose Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma A Randomized Phase III Study of the EORTC Melanoma Group
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to ascertain if the extended schedule of Temozolomide which allows increased doses and potential depletion of the enzyme underlaying resistance is a more effective treatment of metastatic melanoma than single agent dacarbazine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None